TauRx Therapeutics has expanded its international clinical trials by adding new research centres across the USA. The company says the addition of 35 clinical research centres means that more patients suffering from mild or moderate Alzheimer’s, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx’s Alzheimer’s clinical trials
Claude M Wischik, TauRx’s co-founder and chairman, says: “TauRx’s treatment, LMTX, being evaluated in phase III clinical trials for Alzheimer’s, will represent a breakthrough in dementia treatment if, as we hope to demonstrate, it slows and even halts the progression of the disease, as our earlier studies have shown”.
“This compound is potentially a disease-modifying approach to treating Alzheimer’s, targeting the tangles of tau protein that develop in the brain which are clearly linked to the progression of dementia,” says Wischik. “We are pleased to expand the number of research centres conducting our clinical trial to permit more people across the USA to access our study”.
Importantly, adds Wischik, “Only by participating in clinical studies such as ours, can we collectively—in partnership with those living with Alzheimer’s—help advance the essential research that can result in the development of new medicines for this terminal medical condition”.
The main purpose of TauRx’s phase III clinical research studies is to evaluate the effects of LMTX, a second generation tau aggregation inhibitor, on slowing and/or halting the progression of Alzheimer’s disease.
The expansion of study centres in the USA means that eligible patients in areas such as Bennington, Vermont; Farmington Hills, Michigan; Waukesha, Wisconsin; and Creve Coeur, Missouri can also participate in the studies.